On March 5, 2024 IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, reported the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell (CAR-T) platform, INB-300 (Press release, In8bio, MAR 5, 2024, View Source [SID1234640803]). The data will be presented at the 2024 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 5-10, 2024 in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The current generation of CAR-T technology eliminates the target antigen regardless of whether it is expressed on tumor or healthy tissue. IN8bio’s nsCAR platform, INB-300, uses the CAR to traffic and bind to cells expressing the target and leverages the natural innate immune recognition abilities of gamma-delta T cells to distinguish between tumor and healthy tissue. This allows the cells to selectively eliminate cancer cells while leaving healthy cells intact, even when both express the CAR-target.
"We’re excited to share this new data from our nsCAR platform, INB-300, which enables next-generation precision CAR-T therapy by selectively targeting leukemia cells while preserving healthy tissues," said Lawrence Lamb, Ph.D., co-founder and Chief Scientific Officer, IN8bio. "We are using gamma-delta T cells to treat a wide variety of cancers, including myeloid malignancies and solid tumors, where current CAR-T therapy has historically faced significant challenges due to on target, but off tumor toxicities. We look forward to advancing our pipeline of novel gamma-delta based nsCAR therapies for patients with significant unmet need."
AACR Poster Presentation Details
Poster Title: Gamma-delta (γδ) CAR-T cells lacking the CD3ζ signaling domain enhance targeted killing of AML cells and preserve healthy tissues
Abstract Presentation Number: 5227
Session Title: Adoptive Cell Therapies 4
Session Date and Time: Tuesday, April 9, 2024, 1:30pm-5:00pm PT (4:30pm-8:00pm ET)
About INB-300
INB-300 is a non-signaling CAR (nsCAR) gamma-delta T cell platform with several preclinical product candidates, including the INB-330 program against AML targets, that combine our expertise in gamma-delta T cells and genetic engineering. These nsCAR constructs lack signaling domains in order to take advantage of the unique properties of gamma-delta T cells to differentiate between healthy and tumor tissues. IN8bio is advancing new nsCAR constructs against multiple targets to treat both solid and liquid tumors.